<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5445">
  <stage>Registered</stage>
  <submitdate>7/03/2006</submitdate>
  <approvaldate>7/03/2006</approvaldate>
  <nctid>NCT00300131</nctid>
  <trial_identification>
    <studytitle>ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation</studytitle>
    <scientifictitle>Bioabsorbable Vascular Solutions First in Man Clinical Investigation: A Clinical Evaluation of the Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With Single de Novo Native Coronary Artery Lesions</scientifictitle>
    <utrn />
    <trialacronym>ABSORB A</trialacronym>
    <secondaryid>05-370</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Disease</healthcondition>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <healthcondition>Coronary Restenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Bioabsorbable Everolimus Eluting Coronary Stent

1 - Bioabsorbable Vascular Solutions (BVS) Everolimus Eluting Coronary Stent System


Treatment: devices: Bioabsorbable Everolimus Eluting Coronary Stent
Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ischemia Driven MACE</outcome>
      <timepoint>at 30, 180, 270 days, and 1, 2, 3, 4, 5 years;</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Ischemia driven Target Vessel Failure (TVF)</outcome>
      <timepoint>at 30, 180, 270 days, and 1, 2, 3, 4, 5 years;</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Acute success (clinical device and clinical procedure)</outcome>
      <timepoint>Acute</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Ischemia Driven Target Lesion Revascularization (TLR)</outcome>
      <timepoint>at 30, 180, 270 days and 1, 2, 3, 4, 5 years;</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Ischemia Driven Target Vessel Revascularization (TVR)</outcome>
      <timepoint>at 30, 180, 270 days and 1, 2, 3, 4, 5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>In-stent Late Loss(LL)</outcome>
      <timepoint>at 180 days and 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-segment LL</outcome>
      <timepoint>at 180 days and 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proximal LL (proximal defined as within 5 mm of tissue proximal to stent placement)</outcome>
      <timepoint>at 180 days and 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Distal LL (distal defined as within 5 mm of tissue distal to stent placement)</outcome>
      <timepoint>at 180 days and 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-stent and in-segment Angiographic Binary Restenosis (ABR) rate</outcome>
      <timepoint>at 180 days and 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-stent % Volume Obstruction (VO)</outcome>
      <timepoint>at 180 days and 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Persisting incomplete apposition, late incomplete apposition, aneurysm, thrombus, persisting dissection</outcome>
      <timepoint>at 180 days and 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Target lesion must be located in a native epicardial vessel with visually estimated nominal
        vessel diameter of 3.0 mm

          -  Target lesion must measure less/equal 8 mm in length by visual estimation for 3.0 x 12
             mm, expanded to less/equal 14 mm in length by visual estimation when 3.0 x 18 mm stent
             is available

          -  The target lesion(s) must be in a major artery or branch with a visually estimated
             stenosis of &gt; 50% and &lt; 100% with a TIMI flow of greater/equal 1

          -  Non-Clinical Investigation, percutaneous intervention for lesions in a non-target
             vessel is allowed if done more/equal 90 days prior to or if planned to be done 6
             months after the index procedure

          -  Non-Clinical Investigation, percutaneous intervention for lesions in the target vessel
             is allowed if done &gt; 6 months prior to or if planned to be done 6 months after the
             index procedure</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Located within an arterial or saphenous vein graft or distal to a diseased (defined as
             vessel irregularity per angiogram and &gt; 20% stenosed lesion by visual estimation)
             arterial or saphenous vein graft

          -  Lesion involving a bifurcation greater/equal 2 mm in diameter and ostial lesion &gt; 40%
             stenosed by visual estimation or side branch requiring predilatation

          -  Total occlusion (TIMI flow 0), prior to wire passing

          -  The target vessel contains visible thrombus

          -  Another clinically significant lesion is located in the same epicardial vessel
             (including side branch) as the target lesion

          -  Patient has received brachytherapy in any epicardial vessel (including side branches)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>30</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Abbott Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Prospective, open-labeled First in Man Clinical Investigation enrolling patients with
      visually estimated nominal vessel diameter of 3.0 mm receiving a single 3.0 x 12 mm or 3.0 x
      18 mm BVS EECSS containing 98 microgramme per cmÂ² of surface area.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00300131</trialwebsite>
    <publication>Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv. 2007 Jan;69(1):128-31.
TCT Daily: ABSORB: bioabsorbable coronary stents successfully and safely deployed. J Interv Cardiol. 2007 Feb;20(1):36-7.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John Ormiston, MD</name>
      <address>Auckland City Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>